CYL Stock Overview Manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Artivion, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Artivion Historical stock prices Current Share Price US$27.15 52 Week High US$28.30 52 Week Low US$15.20 Beta 1.74 1 Month Change -1.99% 3 Month Change 16.27% 1 Year Change 78.62% 3 Year Change 51.68% 5 Year Change 6.89% Change since IPO 562.52%
Recent News & Updates
Artivion, Inc. Grants FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis Dec 10
Now 20% undervalued Nov 15
Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024 Nov 10
Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024 Nov 09
Third quarter 2024 earnings released: US$0.055 loss per share (vs US$0.24 loss in 3Q 2023) Nov 08
Insufficient new directors Nov 01 See more updates
Artivion, Inc. Grants FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis Dec 10
Now 20% undervalued Nov 15
Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024 Nov 10
Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024 Nov 09
Third quarter 2024 earnings released: US$0.055 loss per share (vs US$0.24 loss in 3Q 2023) Nov 08
Insufficient new directors Nov 01
Artivion, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 25
Independent Director recently sold €221k worth of stock Aug 16
New minor risk - Shareholder dilution Aug 11
Second quarter 2024 earnings released: US$0.051 loss per share (vs US$0.083 loss in 2Q 2023) Aug 09
Artivion, Inc. Revises Earnings Guidance for the Year 2024 Aug 09
Artivion, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
Artivion, Inc. Revises Earnings Guidance for the Year 2024 May 08
First quarter 2024 earnings released: EPS: US$0.18 (vs US$0.33 loss in 1Q 2023) May 07
Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 23
Artivion, Inc., Annual General Meeting, May 14, 2024 Mar 23
New minor risk - Shareholder dilution Mar 22
Chairman recently sold €241k worth of stock Mar 08
Full year 2023 earnings released: US$0.75 loss per share (vs US$0.48 loss in FY 2022) Feb 26
Chairman recently sold €224k worth of stock Feb 23
Artivion, Inc. Provides Earnings Guidance for the Year 2024 Feb 16
Full year 2023 earnings released: US$0.75 loss per share (vs US$0.48 loss in FY 2022) Feb 16
Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Feb 02 Artivion, Inc. announced that it expects to receive $350 million in funding Jan 19
Artivion, Inc. Announces Chief Financial Officer Changes Dec 07
Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial Nov 10
Artivion, Inc. Revises Earnings Guidance for the Year 2023 Nov 03
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.34 loss in 3Q 2022) Nov 03
Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
New minor risk - Share price stability Oct 18
Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting Oct 06
Artivion, Inc. Revises Earnings Guidance for the Full Year 2023 Aug 05
Second quarter 2023 earnings released: US$0.083 loss per share (vs US$0.11 loss in 2Q 2022) Aug 04
Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Senior Vice President of Operations recently sold €232k worth of stock Jun 09
Artivion Revises Earnings Guidance for the Year 2023 May 06
First quarter 2023 earnings released: US$0.34 loss per share (vs US$0.085 loss in 1Q 2022) May 05
Chairman recently sold €276k worth of stock Mar 02
Artivion, Inc. Provides Earnings Outlook for the Year 2023 Feb 18
Full year 2022 earnings released: US$0.48 loss per share (vs US$0.38 loss in FY 2021) Feb 18
Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021) Nov 05
Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022 Nov 05
Artivion, Inc. Provides Revenue Guidance for the Year 2022 Nov 04
Artivion, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Artivion, Inc. Announces the Appointment of Elizabeth A. Hoff to Board of Directors Sep 30
Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial Sep 24
Insider recently sold €122k worth of stock Aug 11
Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.056 loss in 2Q 2021) Aug 05
Artivion, Inc. Provides Financial Guidance for the Year 2022 Aug 05
Artivion Initiates Enrollment in PERSEVERE Clinical Trial Jul 28
Artivion, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
First quarter 2022 earnings released: US$0.085 loss per share (vs US$0.08 loss in 1Q 2021) May 07
Artivion, Inc. Provides Revenue Guidance for the Year 2022 May 06
Insufficient new directors Apr 27 Artivion, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
Artivion, Inc., Annual General Meeting, May 18, 2022 Apr 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 18
Artivion Provides Revenue Guidance for the Full Year 2022 Feb 18
Artivion, Inc. to Report Q4, 2021 Results on Feb 17, 2022 Feb 04
Artivion, Inc. Announces Publication of On-X® Mitral Heart Valve PROACT Study Results in the Annals of Thoracic Surgery Feb 01
Insufficient new directors Dec 06
Director recently bought €231k worth of stock Dec 01
Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.075 loss in 3Q 2020) Nov 06
Insider recently sold €59k worth of stock Aug 25
Insufficient new directors Aug 01
Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.098 loss in 2Q 2020) Jul 31
Insufficient new directors Jul 30 CryoLife, Inc.(NYSE:CRY) dropped from Russell 2000 Value-Defensive Index
CryoLife, Inc.(NYSE:CRY) dropped from Russell 2000 Defensive Index Jun 27
Cryolife, Inc. Not to Provide Full Year 2021 Financial Guidance Apr 30
CryoLife, Inc. Announces Retirement of Michael S. Simpson as Senior Vice President, Regulatory Affairs and Quality Assurance Mar 09
CryoLife, Inc. Is Not Issuing 2021 Financial Guidance Feb 13
Revenue beats expectations Feb 12
Full year 2020 earnings released: US$0.44 loss per share (vs US$0.046 profit in FY 2019) Feb 12
New 90-day high: €21.20 Feb 11
CryoLife, Inc. to Report Q4, 2020 Results on Feb 11, 2021 Jan 29
Cryolife, Inc. Not to Provide Earnings Guidance for the Year 2020 Nov 06 CryoLife, Inc. (NYSE:CRY) acquired Ascyrus Medical LLC from a group of shareholders for approximately $220 million. Sep 16
Shareholder Returns CYL DE Medical Equipment DE Market 7D -1.8% -0.01% -0.1% 1Y 78.6% -8.8% 7.4%
See full shareholder returns
Return vs Market: CYL exceeded the German Market which returned 7.4% over the past year.
Price Volatility Is CYL's price volatile compared to industry and market? CYL volatility CYL Average Weekly Movement 3.9% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CYL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CYL's weekly volatility (4%) has been stable over the past year.
About the Company Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
Show more Artivion, Inc. Fundamentals Summary How do Artivion's earnings and revenue compare to its market cap? CYL fundamental statistics Market cap €1.13b Earnings (TTM ) -€817.08k Revenue (TTM ) €373.51m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CYL income statement (TTM ) Revenue US$384.90m Cost of Revenue US$136.53m Gross Profit US$248.37m Other Expenses US$249.22m Earnings -US$842.00k
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.02 Gross Margin 64.53% Net Profit Margin -0.22% Debt/Equity Ratio 103.0%
How did CYL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/06 16:06 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Artivion, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raymond Myers Benchmark Company Jason Mills Canaccord Genuity Raymond Myers Emerging Growth Equities, Ltd.
Show 11 more analysts 
